SAB Biotherapeutics Inc
Change company Symbol lookup
Select an option...
SABS SAB Biotherapeutics Inc
DIA SPDR® Dow Jones Industrial Average ETF Trust
SPY SPDR® S&P 500 ETF Trust
FCF First Commonwealth Financial Corp
ARMN Aris Mining Corp
IBM International Business Machines Corp
JPM JPMorgan Chase & Co
GEHC GE Healthcare Technologies Inc
GE General Electric Co

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. Its DiversitAb platform is applicable to a range of serious unmet needs in human diseases. It produces fully human polyclonal immunotherapies without the need for human donors. Its product candidates include SAB-185, a fully human polyclonal antibody therapeutic for the treatment of coronavirus disease, and SAB-176, a multivalent, neutralizing fully human polyclonal antibody therapeutic candidate designed to bind to Type A and B influenza viruses. Its preclinical stage assets SAB-195 is the first-in-class fully human hIgG treatment for the treatment of Clostridioides difficile infection (CDI), and SAB-142 is a multi-indication potential asset developed for organ transplant induction and organ transplant rejection, among other immunological indications.

Day's Change
0.0191 (2.89%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 82,337 shares is on pace to be much greater than SABS's 10-day average volume of 68,370 shares.


Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.